01 May 2015
On 13th March 2015 the marketing authorisation of Lynoral has been transferred from NV Organon to ACE Pharmaceuticals BV.
Being the new marketing authorisation holder, ACE has changed the product name:
Lynoral 0,05 mg has now become Acelyn 0,05 mg
Ethinylestradiol 0,05 mg (NL-RVG 00022)
The packaging will change accordingly. Cartons of Lynoral that are still in the market can continued to be supplied.
The primary indication of Acelyn is ‘treatment of constitutional long length in girls’. The break line enables doses of 25 microgram.